The Charles T. Campbell Eye Microbiology Lab
UPMC | University of Pittsburgh Medical CenterUniversity of Pittsburgh Schools of the Health Sciences
HomeAbout UsLab Diagnostic TestingAntibiotic SusceptibilityAntimicrobial TherapyCurrent ResearchContact Us

2001 Ocular Microbiology and Immunology Group, Abstract 2

OMIG Main Page | 2001 Abstracts| < Previous | Next>

The Effects of Topical Xalatan on Recovery of Ocular HSV-1 Associated with Induced Reactivation and Spontaneous Shedding
F.S. Mah, E. Romanowski, K.A. Yates and Y.J. Gordon
The Charles T. Campbell Laboratory, University of Pittsburgh, Pittsburgh, PA

Purpose:. Xalatan (Xal) treatment has been clinically and experimentally associated with recurrences of herpetic keratins. Our goal was to determine the effects of topical Xal and its components on the recovery of ocular HSV-1 associated with induced reactivation and spontaneous shedding in the HSV-1/NZW rabbit latency model using virological outcome measures.

Methods: HSV-1 latently-infected rabbits from both the induced reactivation and spontaneous shedding studies were divided into 6 topical treatment groups. I) Xal; II) 0.05% latanoprost (Latan);III 0.02% benzalkonium chloride (BAK); IV) 0.02% benzalkonium chloride BID (BAKx2); V) Saline control (Con) BID; VI) Latan vehicle (L-Veh). Treatment was QD unless noted. Induced reactivation (IR): 74 rabbits received intrastromal injections of water in both eyes to induce reactivation of latent HSV-1. All eyes were then treated and cultured for 10 days. Data was expressed as HSV-IR Positive Eyes/total and as the mean IR shedding days/eye. Spontaneous shedding (SS): 49 rabbits were treated and cultured in both eyes for 30 days. Data was expressed as HSV-1 Spontaneous Shedding Episodes (SSE)/total and as the mean shedding days/SSE. All cultures were plated on Vero cells and examined for HSV-1CPE.


Gr. IR+Eyes/Tot IR Shed Days/Eye SSE/Total Shed Days/SSE
Xal 18/24(75%) 3.0 ±1.8 20/121(17%)

3.0 ±1.9

Latan 15/26(58%) 4.8 ±1.8 22/121(18%)

2.0 ±1.6

BAK 16/24(67%) 3.1 ±2.1 28/121(23%)

1.8 ±1.6

BAKx2 20/24(83%) 3.0 ±2.1 20/121(17%)

2.1 ± 1.5

Con 18/26(69%) 3.7±2.8 15/121(12%)

2.3 ±1.8

L-Veh 18/23(78%) 2.8 ±1.8 16/121(13%)

2.8 ±2.1

There were no differences among the groups for all analyses.

Conclusions: Neither Xalatan nor any of its components induced or promoted reactivation of latent HSV-1 and did not prolong shedding of HSV-1 on the ocular surface after a reactivation event in the HSV-1/NZW rabbit latency model. Administration of 0.02% BAK BID had no effect on HSV-1 reactivation and shedding.

Support: Nffl Core Grant EY08098, Pharmacia Corp, and RPB

OMIG Main Page | 2001 Abstracts| < Previous | Next>

Top of Page

Web Site Terms of Use | E-mail Terms of Use | Medical Advice Disclaimer
UPMC | Affiliated with the University of Pittsburgh Schools of the Health Sciences | Contact UPMC